Basic Information
RNALocate ID: | RLID:11001933 |
RNA Symbol: | hsa-miR-154-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-154-5p |
RNA ID: | miRBase:MIMAT0000452 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001838 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:11001932 | Exosome | Brain tissue | 23382797 |
RLID-D:11000380 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
RLID-D:11001180 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-154-5p | Oral squamous cell carcinoma | MNDR-E-MI-17418 |
MNDR | hsa-miR-154-5p | Medulloblastoma | MNDR-E-MI-17419 |
MNDR | hsa-miR-154-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-17420 |
MNDR | hsa-miR-154-5p | Ovarian clear cell carcinoma | MNDR-E-MI-17421 |
MNDR | hsa-miR-154-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-17422 |
MNDR | hsa-miR-154-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-17423 |
MNDR | hsa-miR-154-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-17424 |
MNDR | hsa-miR-154-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-17425 |
MNDR | hsa-miR-154-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-17426 |
MNDR | hsa-miR-154-5p | Her2-receptor positive breast cancer | MNDR-E-MI-17427 |
MNDR | hsa-miR-154-5p | Breast cancer luminal | MNDR-E-MI-17428 |
MNDR | hsa-miR-154-5p | Dermatomyositis | MNDR-E-MI-17429 |
MNDR | hsa-miR-154-5p | Prostate cancer | MNDR-E-MI-17430 |
MNDR | hsa-miR-154-5p | Gastric cancer | MNDR-E-MI-17431 |
MNDR | hsa-miR-154-5p | Alzheimer disease | MNDR-E-MI-17432 |
MNDR | hsa-miR-154-5p | Bladder cancer | MNDR-E-MI-17433 |
MNDR | hsa-miR-154-5p | Dysautonomia familial | MNDR-E-MI-17434 |
MNDR | hsa-miR-154-5p | Muscular dystrophy duchenne | MNDR-E-MI-17435 |
MNDR | hsa-miR-154-5p | Facioscapulohumeral muscular dystrophy | MNDR-E-MI-17436 |
MNDR | hsa-miR-154-5p | Head and neck cancer | MNDR-E-MI-17437 |
MNDR | hsa-miR-154-5p | Huntington disease | MNDR-E-MI-17438 |
MNDR | hsa-miR-154-5p | Lung cancer | MNDR-E-MI-17439 |
MNDR | hsa-miR-154-5p | Endometrial cancer | MNDR-E-MI-17440 |
MNDR | hsa-miR-154-5p | Parkinson disease | MNDR-E-MI-17441 |
MNDR | hsa-miR-154-5p | Breast cancer | MNDR-E-MI-17442 |
MNDR | hsa-miR-154-5p | Thyroid cancer | MNDR-E-MI-17443 |
MNDR | hsa-miR-154-5p | Pituitary neoplasms | MNDR-E-MI-17444 |
MNDR | hsa-miR-154-5p | Pancreatic cancer | MNDR-E-MI-17445 |
MNDR | hsa-miR-154-5p | Melanoma | MNDR-E-MI-17446 |
MNDR | hsa-miR-154-5p | Nephroblastoma | MNDR-E-MI-17447 |
MNDR | hsa-miR-154-5p | Colon cancer | MNDR-E-MI-17448 |
MNDR | hsa-miR-154-5p | Familial ovarian cancer | MNDR-E-MI-17449 |
MNDR | hsa-miR-154-5p | Prostate adenocarcinoma | MNDR-E-MI-17450 |
MNDR | hsa-miR-154-5p | Carcinoma ductal breast | MNDR-E-MI-17451 |
MNDR | hsa-miR-154-5p | Balkan nephropathy | MNDR-E-MI-17452 |
MNDR | hsa-miR-154-5p | Glioblastoma | MNDR-E-MI-17453 |
MNDR | hsa-miR-154-5p | Astrocytoma | MNDR-E-MI-17454 |
MNDR | hsa-miR-154-5p | Glioma | MNDR-E-MI-17455 |
MNDR | hsa-miR-154-5p | Nemaline myopathy | MNDR-E-MI-17456 |
MNDR | hsa-miR-154-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-17457 |
MNDR | hsa-miR-154-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-17458 |
MNDR | hsa-miR-154-5p | Meningioma | MNDR-E-MI-17459 |
MNDR | hsa-miR-154-5p | Uterine cancer | MNDR-E-MI-17460 |
MNDR | hsa-miR-154-5p | Gastric adenocarcinoma | MNDR-E-MI-17461 |
MNDR | hsa-miR-154-5p | Cervical squamous cell carcinoma | MNDR-E-MI-17462 |
MNDR | hsa-miR-154-5p | Bone-invasive pituitary adenoma | MNDR-E-MI-17463 |
MNDR | hsa-miR-154-5p | Lung adenocarcinoma | MNDR-E-MI-17464 |
MNDR | hsa-miR-154-5p | Adrenocortical carcinoma | MNDR-E-MI-17465 |
MNDR | hsa-miR-154-5p | Thyroid carcinoma | MNDR-E-MI-17466 |
MNDR | hsa-miR-154-5p | Ovarian carcinoma | MNDR-E-MI-17467 |
MNDR | hsa-miR-154-5p | Bladder urothelial carcinoma | MNDR-E-MI-17468 |
MNDR | hsa-miR-154-5p | Pancreatic adenocarcinoma | MNDR-E-MI-17469 |
MNDR | hsa-miR-154-5p | Carcinoma renal cell | MNDR-E-MI-17470 |
MNDR | hsa-miR-154-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-17471 |
MNDR | hsa-miR-154-5p | Renal clear cell carcinoma | MNDR-E-MI-17472 |
MNDR | hsa-miR-154-5p | Cholangiocarcinoma | MNDR-E-MI-17473 |
MNDR | hsa-miR-154-5p | Esophageal cancer | MNDR-E-MI-17474 |
MNDR | hsa-miR-154-5p | Synovial sarcoma | MNDR-E-MI-17475 |
MNDR | hsa-miR-154-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-17476 |
MNDR | hsa-miR-154-5p | T acute lymphoblastic leukemia | MNDR-E-MI-17477 |
MNDR | hsa-miR-154-5p | Acute t cell leukemia | MNDR-E-MI-17478 |
MNDR | hsa-miR-154-5p | Breast invasive carcinoma | MNDR-E-MI-17479 |
MNDR | hsa-miR-154-5p | Hepatocellular carcinoma | MNDR-E-MI-17480 |
MNDR | hsa-miR-154-5p | Familiar ovarian carcinoma | MNDR-E-MI-17481 |
MNDR | hsa-miR-154-5p | Neuroblastoma | MNDR-E-MI-17482 |
MNDR | hsa-miR-154-5p | Colorectal cancer | MNDR-E-MI-17483 |
MNDR | hsa-miR-154-5p | Nasopharynx carcinoma | MNDR-E-MI-17484 |
MNDR | hsa-miR-154-5p | Nasopharyngeal cancer | MNDR-E-MI-17485 |
MNDR | hsa-miR-154-5p | Prostatic neoplasms | MNDR-E-MI-17486 |
MNDR | hsa-miR-154-5p | Polymyositis | MNDR-E-MI-17487 |
MNDR | hsa-miR-154-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-17488 |
MNDR | hsa-miR-154-5p | Breast cancer her3+ negative | MNDR-E-MI-17489 |
MNDR | hsa-miR-154-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-17490 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | CCND2 | Homo sapiens | RR00295032 |
TOP